Human Cardiac Myocytes Search Results


human cardiac cells  (Innoprot Inc)
91
Innoprot Inc human cardiac cells
Human Cardiac Cells, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cardiac cells/product/Innoprot Inc
Average 91 stars, based on 1 article reviews
human cardiac cells - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
cardiac myocytes  (Axol Bioscience)
93
Axol Bioscience cardiac myocytes
Cardiac Myocytes, supplied by Axol Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cardiac myocytes/product/Axol Bioscience
Average 93 stars, based on 1 article reviews
cardiac myocytes - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
primary human ventricular cardiac myocytes  (CellSystems Biotechnologie Vertrieb GmbH)
90
CellSystems Biotechnologie Vertrieb GmbH primary human ventricular cardiac myocytes
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Primary Human Ventricular Cardiac Myocytes, supplied by CellSystems Biotechnologie Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary human ventricular cardiac myocytes/product/CellSystems Biotechnologie Vertrieb GmbH
Average 90 stars, based on 1 article reviews
primary human ventricular cardiac myocytes - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human cardiac myocytes catalog no. 6200  (ScienCell)
90
ScienCell human cardiac myocytes catalog no. 6200
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Human Cardiac Myocytes Catalog No. 6200, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cardiac myocytes catalog no. 6200/product/ScienCell
Average 90 stars, based on 1 article reviews
human cardiac myocytes catalog no. 6200 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cryopreserved vials of icell human cardiac myocytes  (iCell Gene Therapeutics)
90
iCell Gene Therapeutics cryopreserved vials of icell human cardiac myocytes
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Cryopreserved Vials Of Icell Human Cardiac Myocytes, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cryopreserved vials of icell human cardiac myocytes/product/iCell Gene Therapeutics
Average 90 stars, based on 1 article reviews
cryopreserved vials of icell human cardiac myocytes - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cardiac myocytes derived human ipscs  (FUJIFILM)
90
FUJIFILM cardiac myocytes derived human ipscs
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Cardiac Myocytes Derived Human Ipscs, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cardiac myocytes derived human ipscs/product/FUJIFILM
Average 90 stars, based on 1 article reviews
cardiac myocytes derived human ipscs - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human cardiac myocyte cdna library sc6204  (3H Biomedical)
90
3H Biomedical human cardiac myocyte cdna library sc6204
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Human Cardiac Myocyte Cdna Library Sc6204, supplied by 3H Biomedical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cardiac myocyte cdna library sc6204/product/3H Biomedical
Average 90 stars, based on 1 article reviews
human cardiac myocyte cdna library sc6204 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human cardiac muscle cell human cardiac myocytes  (ScienCell)
90
ScienCell human cardiac muscle cell human cardiac myocytes
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Human Cardiac Muscle Cell Human Cardiac Myocytes, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cardiac muscle cell human cardiac myocytes/product/ScienCell
Average 90 stars, based on 1 article reviews
human cardiac muscle cell human cardiac myocytes - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human cardiac myocyte cell line scc109  (Merck KGaA)
90
Merck KGaA human cardiac myocyte cell line scc109
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Human Cardiac Myocyte Cell Line Scc109, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cardiac myocyte cell line scc109/product/Merck KGaA
Average 90 stars, based on 1 article reviews
human cardiac myocyte cell line scc109 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
human cardiac myocytes media  (ScienCell)
90
ScienCell human cardiac myocytes media
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Human Cardiac Myocytes Media, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human cardiac myocytes media/product/ScienCell
Average 90 stars, based on 1 article reviews
human cardiac myocytes media - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
icell® human cardiac myocytes  (iCell Gene Therapeutics)
90
iCell Gene Therapeutics icell® human cardiac myocytes
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Icell® Human Cardiac Myocytes, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/icell® human cardiac myocytes/product/iCell Gene Therapeutics
Average 90 stars, based on 1 article reviews
icell® human cardiac myocytes - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
fetal human cardiac myocytes (hcm) catalog number 6200  (ScienCell)
90
ScienCell fetal human cardiac myocytes (hcm) catalog number 6200
(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of <t>ventricular</t> dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).
Fetal Human Cardiac Myocytes (Hcm) Catalog Number 6200, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fetal human cardiac myocytes (hcm) catalog number 6200/product/ScienCell
Average 90 stars, based on 1 article reviews
fetal human cardiac myocytes (hcm) catalog number 6200 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


(a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of ventricular dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).

Journal: PLoS ONE

Article Title: Anti-Thymocyte Globulin Induces Neoangiogenesis and Preserves Cardiac Function after Experimental Myocardial Infarction

doi: 10.1371/journal.pone.0052101

Figure Lengend Snippet: (a) Hearts obtained from untreated control animals evidenced an extensive scar size and signs of ventricular dilation, whereas scar size was reduced in ATG injected rats with a better preserved ventricular geometry (b). ATG injection after AMI resulted in a reduction of scar size from 24.95% of the left ventricle in untreated controls to 11.43% in the treatment group, p<0.01, n = 9–13 per group). Parameters of cardiac function (ejection fraction, shortening fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter) were significantly improved by ATG (d,e,f,g).

Article Snippet: Primary human ventricular cardiac myocytes were obtained from CellSystems (CellSystems Biotechnologie, St. Katharinen, Germany) and were cultured in cardiac myocyte medium (CellSystems) at 37°C at a cell density of 3*10 5 in 6-well plates for 24 hours.

Techniques: Control, Injection